Evaluation of anti-inflammatory and antinociceptive activity of Triphala recipe

Safety of the Oral Triphala Recipe from Acute and Chronic Toxicity Tests in Sprague-Dawley Rats

BACKGROUND

The Indian Ayurvedic herbal formula Triphala (TPL) is known for its pharmacological properties for immunomodulation, anti-inflammation, antioxidant, and anti-cancer. This study aimed to investigate the acute and chronic toxicities of the Triphala recipe in a rat model.

METHODS

To assess the acute toxicities, 5000 mg/kg of TPL was orally administered to Sprague-Dawley rats. For chronic toxicities, different dose levels of TPL at 600, 1200, and 2400 mg/kg/day were given daily for 270 days. General health and behaviors and the body and organ weights of the rats were monitored. At the end of the experiment, blood samples were evaluated for hematology and biochemistry profiles. The evaluation of the internal organs' appurtenance and necropsy was performed to confirm the tissue histopathology.

RESULTS

The results showed that there was no sign of acute toxicity in the TPL group with a decrease in sex organ weights. No significant differences in the rats' behaviors, physical health, body, or organ weights were found between the controls and the rats receiving the 270/day of oral Triphala at 600, 1200, and 2400 mg/kg/day. However, some alterations in blood chemistries and hematology, including glucose, BUN, red blood cells, Hb, HCT, and MCV, were observed without abnormalities in histopathology.

CONCLUSIONS

It has been demonstrated that the long-term use of TPL in rat models is safe. No toxic effects were found, suggesting possible safety for long-term use in humans.

ASPP 092, a phenolic diarylheptanoid from Curcuma comosa suppresses experimentally-induced inflammatory ear edema in mice

Curcuma comosa Roxb., family Zingiberaceae, exhibits diverse biological activities. This study was aimed to investigate the anti-inflammatory potential of a major phenolic diarylheptanoid isolated from C. comosa, ASPP 092 [(3S)-1-(3,4-dihydroxy-phenyl)-7-phenyl-(6E)-6-hepten-3-ol] in an experimentally-induced inflammatory ear edema model in mice. Ear edema in the mice was induced by the topical application of irritant, ethyl phenylpropiolate (EPP). The topical application of ASPP 092 at the edema site was directed immediately after the EPP application. The edematous responses were assessed at different time points by measuring the thickness of each ear before and after the EPP application followed by histopathology analysis. The expressions of major inflammatory cytokines were analyzed by real-time RT-PCR followed by the immunohistochemistry analysis of cyclooxygenase (COX-2). The topical application of ASPP 092 effectively suppressed the EPP-induced edematous formation in the ear of mice. Histopathological analysis showed substantial improvements in epidermal hyperplasia and inflammatory cell infiltration. ASPP 092 treatment also modulated the expressions of inflammatory cytokines including Tumor Necrosis Factor-α (TNF-α), interleukin-6 (IL-6), interleukin-10 (IL-10), interleukin-1β (IL-1β), and Matrix metalloproteinase-13 (MMP-13). The expressions of cyclooxygenases (COX) including COX-1 and COX-2 were significantly reduced by ASPP 092 treatment. For the first time, our results suggest the efficacy of ASPP 092 to suppress experimentally-induced inflammation in a preclinical model in mice; however, a more detailed evaluation of its mechanism of action is necessary before evaluating its efficacy and safety in randomized trials.

Pharmacological Benefits of Triphala: A Perspective for Allergic Rhinitis

Allergic rhinitis (AR) is considered a major nasal condition impacting a large number of people around the world, and it is now becoming a global health problem. Because the underlying mechanisms of AR are complex, the development of single-drug treatment might not be enough to treat a wide spectrum of the disease. Although the standard guidelines classify and provide suitable diagnosis and treatment, the vast majority of people with AR are still without any means of controlling it. Moreover, the benefits of AR drugs are sometimes accompanied by undesirable side effects. Thus, it is becoming a significant challenge to find effective therapies with limited undesirable side effects for a majority of patients suffering from uncontrolled AR. Aller-7/NR-A2, a polyherbal formulation, has revealed promising results in patients by reducing nasal symptoms and eosinophil counts without serious adverse effects. Interestingly, three out of seven of the herbals in the Aller-7/NR-A2 formulation are also found in an Ayurvedic polyherbal formulation known as “Triphala,” which is a potential candidate for the treatment of AR. However, there are no current studies that have examined the effects of Triphala on the disease. This review aims to describe the complexity of AR pathophysiology, currently available treatments, and the effects of Triphala on AR in order to help develop it as a promising alternative treatment in the future.

Triphala extract negates arecoline-induced senescence in oral mucosal epithelial cells in vitro

Background

Arecoline found in areca nut causes oral submucous fibrosis. Triphala is an Ayurvedic medicinal preparation used to improve overall physical wellness that has also been shown to improve oral health.

Objectives

To assess the activity of Triphala extract on arecoline-induced senescence in oral mucosal epithelial cells in vitro.

Materials and methods

Oral mucosal epithelial cells were isolated and cultured in vitro. A 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay was performed to assess the viability of treated cells, while senescence was assessed by senescence-associated-β-galactosidase staining. Cell surface marker expression was analyzed by flow cytometry. Finally, real-time quantitative polymerase chain reaction was performed to examine gene expression levels.

Results

Triphala extract (5 µg/mL) reversed the cell senescence activity of arecoline, as evidenced by reduced β-galactosidase activity, increased Ki-67 marker expression, and reduced expression of senescence-related genes p16 and p21.

Conclusion

Triphala extract helped to reduce the pathological effects of arecoline-induced pathogenesis.

Clinical relevance.

Arecoline found in the areca nut causes oral pathological conditions including oral submucous fibrosis. Our results showed that Triphala counteracted the adverse effects of arecoline, in particular, negating senescence in oral mucosal epithelial cells. As a translational effect, Triphala treatment could restore normal epithelial thickness in oral submucous fibrosis, thus reducing the clinical severity of the disease. This reestablishment of oral homeostasis would help to improve oral health-related quality of life in patients with oral submucous fibrosis.

Effect of Triphala on dextran sulphate sodium-induced colitis in rats

Background:

Herbal products from Ayurveda were always in the forefront in providing leads to new drug discovery. Triphala, an ancient Ayurvedic herbal formulation comprises of equal portions of Amalaki, Bibhitaki and Haritaki and is used extensively for constipation, as an anti-inflammatory, analgesic, anti-arthritic, hypoglycemic and an anti-aging agent.

Aim:

To evaluate the effect of Triphala on dextran sulphate sodium induced colitis in rats.

Materials and Methods:

Present study carried out in total five groups (n = 6 in each group); first group served as normal, second group control, third group standard control and remaining two as test drug groups. Mesalzine was used as a standard drug for comparison. Two doses (150 mg/kg and 300 mg/kg) of Triphala were given as treatment for two separate groups of colitis rats for 7 days. C-reactive protein, superoxide dismutase, catalase, malondialdehyde levels were evaluated and histological study of the distal colon was conducted.

Results:

The colitis rats treated with higher dose of Triphala (300 mg/kg) exhibited normal parameters similar to normal control group animals, which is on par with standard drug mesalzine effect.

Conclusion:

The results suggest that Triphala (300 mg/kg) has a considerable and reliable effect in reducing colitis in rats. This effect can be attributed to its antioxidant activity and well presence of flavonoids.